Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, Andrés J M Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria Giuseppina Cabras, Luigi Rigacci, Livio Gargantini, Francesco Merli, Graziella Pinotti, Donato Mannina, Stefano Luminari, Anastasios Stathis, Eleonora Russo, Franco Cavalli, Luca Giovanella, Peter W M Johnson, Emanuele Zucca

Research output: Contribution to journalArticle

Abstract

The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed to evaluate the role of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) in the management of primary mediastinal (thymic) large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET parameters at diagnosis. Metabolic activity defined by the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was measured on baseline 18FDG PET/CT following a standard protocol in a prospectively enrolled cohort of 103 PMBCL patients. All received combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 had consolidation radiotherapy. Cut-off values were determined using the receiver-operating characteristic curve. At a median follow-up of 36 months, progression-free survival (PFS) and overall survival (OS) were 87% and 94%, respectively. In univariate analysis, elevated MTV and TLG were significantly associated with worse PFS and OS. Only TLG retained statistical significance for both OS (P = .001) and PFS (P <.001) in multivariate analysis. At 5 years, OS was 100% for patients with low TLG vs 80% for those with high TLG (P = .0001), whereas PFS was 99% vs 64%, respectively (P <.0001). TLG on baseline PET appeared to be a powerful predictor of PMBCL outcomes and warrants further validation as a biomarker. The IELSG 26 study was registered at www.clinicaltrials.gov as #NCT00944567.

Original languageEnglish
Pages (from-to)950-956
Number of pages7
JournalBlood
Volume126
Issue number8
DOIs
Publication statusPublished - Aug 20 2015

Fingerprint

Positron emission tomography
Fluorodeoxyglucose F18
B-Cell Lymphoma
Glycolysis
Tomography
Cells
Disease-Free Survival
Survival
Tumor Burden
Tumors
Lymphoma
Radiotherapy
Biomarkers
ROC Curve
Consolidation
Doxorubicin
Positron Emission Tomography Computed Tomography
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. / Ceriani, Luca; Martelli, Maurizio; Zinzani, Pier Luigi; Ferreri, Andrés J M; Botto, Barbara; Stelitano, Caterina; Gotti, Manuel; Cabras, Maria Giuseppina; Rigacci, Luigi; Gargantini, Livio; Merli, Francesco; Pinotti, Graziella; Mannina, Donato; Luminari, Stefano; Stathis, Anastasios; Russo, Eleonora; Cavalli, Franco; Giovanella, Luca; Johnson, Peter W M; Zucca, Emanuele.

In: Blood, Vol. 126, No. 8, 20.08.2015, p. 950-956.

Research output: Contribution to journalArticle

Ceriani, L, Martelli, M, Zinzani, PL, Ferreri, AJM, Botto, B, Stelitano, C, Gotti, M, Cabras, MG, Rigacci, L, Gargantini, L, Merli, F, Pinotti, G, Mannina, D, Luminari, S, Stathis, A, Russo, E, Cavalli, F, Giovanella, L, Johnson, PWM & Zucca, E 2015, 'Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma', Blood, vol. 126, no. 8, pp. 950-956. https://doi.org/10.1182/blood-2014-12-616474
Ceriani, Luca ; Martelli, Maurizio ; Zinzani, Pier Luigi ; Ferreri, Andrés J M ; Botto, Barbara ; Stelitano, Caterina ; Gotti, Manuel ; Cabras, Maria Giuseppina ; Rigacci, Luigi ; Gargantini, Livio ; Merli, Francesco ; Pinotti, Graziella ; Mannina, Donato ; Luminari, Stefano ; Stathis, Anastasios ; Russo, Eleonora ; Cavalli, Franco ; Giovanella, Luca ; Johnson, Peter W M ; Zucca, Emanuele. / Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. In: Blood. 2015 ; Vol. 126, No. 8. pp. 950-956.
@article{a133b0bc084543c9bdadf1b51c11e357,
title = "Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma",
abstract = "The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed to evaluate the role of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) in the management of primary mediastinal (thymic) large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET parameters at diagnosis. Metabolic activity defined by the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was measured on baseline 18FDG PET/CT following a standard protocol in a prospectively enrolled cohort of 103 PMBCL patients. All received combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 had consolidation radiotherapy. Cut-off values were determined using the receiver-operating characteristic curve. At a median follow-up of 36 months, progression-free survival (PFS) and overall survival (OS) were 87{\%} and 94{\%}, respectively. In univariate analysis, elevated MTV and TLG were significantly associated with worse PFS and OS. Only TLG retained statistical significance for both OS (P = .001) and PFS (P <.001) in multivariate analysis. At 5 years, OS was 100{\%} for patients with low TLG vs 80{\%} for those with high TLG (P = .0001), whereas PFS was 99{\%} vs 64{\%}, respectively (P <.0001). TLG on baseline PET appeared to be a powerful predictor of PMBCL outcomes and warrants further validation as a biomarker. The IELSG 26 study was registered at www.clinicaltrials.gov as #NCT00944567.",
author = "Luca Ceriani and Maurizio Martelli and Zinzani, {Pier Luigi} and Ferreri, {Andr{\'e}s J M} and Barbara Botto and Caterina Stelitano and Manuel Gotti and Cabras, {Maria Giuseppina} and Luigi Rigacci and Livio Gargantini and Francesco Merli and Graziella Pinotti and Donato Mannina and Stefano Luminari and Anastasios Stathis and Eleonora Russo and Franco Cavalli and Luca Giovanella and Johnson, {Peter W M} and Emanuele Zucca",
year = "2015",
month = "8",
day = "20",
doi = "10.1182/blood-2014-12-616474",
language = "English",
volume = "126",
pages = "950--956",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

AU - Ceriani, Luca

AU - Martelli, Maurizio

AU - Zinzani, Pier Luigi

AU - Ferreri, Andrés J M

AU - Botto, Barbara

AU - Stelitano, Caterina

AU - Gotti, Manuel

AU - Cabras, Maria Giuseppina

AU - Rigacci, Luigi

AU - Gargantini, Livio

AU - Merli, Francesco

AU - Pinotti, Graziella

AU - Mannina, Donato

AU - Luminari, Stefano

AU - Stathis, Anastasios

AU - Russo, Eleonora

AU - Cavalli, Franco

AU - Giovanella, Luca

AU - Johnson, Peter W M

AU - Zucca, Emanuele

PY - 2015/8/20

Y1 - 2015/8/20

N2 - The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed to evaluate the role of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) in the management of primary mediastinal (thymic) large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET parameters at diagnosis. Metabolic activity defined by the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was measured on baseline 18FDG PET/CT following a standard protocol in a prospectively enrolled cohort of 103 PMBCL patients. All received combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 had consolidation radiotherapy. Cut-off values were determined using the receiver-operating characteristic curve. At a median follow-up of 36 months, progression-free survival (PFS) and overall survival (OS) were 87% and 94%, respectively. In univariate analysis, elevated MTV and TLG were significantly associated with worse PFS and OS. Only TLG retained statistical significance for both OS (P = .001) and PFS (P <.001) in multivariate analysis. At 5 years, OS was 100% for patients with low TLG vs 80% for those with high TLG (P = .0001), whereas PFS was 99% vs 64%, respectively (P <.0001). TLG on baseline PET appeared to be a powerful predictor of PMBCL outcomes and warrants further validation as a biomarker. The IELSG 26 study was registered at www.clinicaltrials.gov as #NCT00944567.

AB - The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed to evaluate the role of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) in the management of primary mediastinal (thymic) large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET parameters at diagnosis. Metabolic activity defined by the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was measured on baseline 18FDG PET/CT following a standard protocol in a prospectively enrolled cohort of 103 PMBCL patients. All received combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 had consolidation radiotherapy. Cut-off values were determined using the receiver-operating characteristic curve. At a median follow-up of 36 months, progression-free survival (PFS) and overall survival (OS) were 87% and 94%, respectively. In univariate analysis, elevated MTV and TLG were significantly associated with worse PFS and OS. Only TLG retained statistical significance for both OS (P = .001) and PFS (P <.001) in multivariate analysis. At 5 years, OS was 100% for patients with low TLG vs 80% for those with high TLG (P = .0001), whereas PFS was 99% vs 64%, respectively (P <.0001). TLG on baseline PET appeared to be a powerful predictor of PMBCL outcomes and warrants further validation as a biomarker. The IELSG 26 study was registered at www.clinicaltrials.gov as #NCT00944567.

UR - http://www.scopus.com/inward/record.url?scp=84940039379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940039379&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-12-616474

DO - 10.1182/blood-2014-12-616474

M3 - Article

C2 - 26089397

AN - SCOPUS:84940039379

VL - 126

SP - 950

EP - 956

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -